-- Record 2017 revenue of $237 million –
--Q4 2017 net income of $0.58 per diluted share
and Adjusted Non-GAAP net income of $1.00 per diluted share --
-- FY 2017 net income of $3.27 per diluted
share and Adjusted Non-GAAP net income of $4.34 per diluted share
--
-- Agreed on path forward with the FDA for an
additional clinical trial for RYANODEX for Exertional Heat Stroke
--
Eagle Pharmaceuticals, Inc. (“Eagle” or “the Company”) (Nasdaq:
EGRX) today announced its financial results for the three- and
twelve-months ended December 31, 2017. Highlights of and subsequent
to the fourth quarter of 2017 include:
Business and Recent Highlights:
- Agreed on a path forward with the FDA
for RYANODEX® for EHS and plans to conduct an additional clinical
trial in August 2018 during the Hajj pilgrimage, similar to the
Eagle study conducted during the Hajj in 2015;
- Completed randomization of 600 subjects
in the fulvestrant clinical study ahead of schedule during the
first quarter of 2018;
- Filed an ANDA for Eagle’s first of two
ANDA product candidates in 2018; awaiting FDA acceptance;
- Settled $48mm in potential Arsia
milestone obligations in exchange for $15 million in cash, for a
total investment in Eagle Biologics of $45 million.
Financial Highlights:
Fourth Quarter 2017
- Total revenue for the fourth quarter of
2017 was $46.8 million, compared to $81.1 million in the fourth
quarter of 2016, which included $40 million in license and other
income;
- Q4 2017 income before income tax
provision was $9.9 million compared to $28.3 million in Q4
2016;
- Q4 2017 net income was $9.1 million, or
$0.61 per basic and $0.58 per diluted share, compared to net income
of $57.3 million, or $3.75 per basic and $3.52 per diluted share in
Q4 2016;
- Q4 2017 Adjusted Non-GAAP net income
was $15.6 million, or $1.05 per basic and $1.00 per diluted share,
compared to Adjusted Non-GAAP net income of $17.2 million, or $1.12
per basic and $1.05 per diluted share in the prior year
quarter.
Full Year 2017
- Total revenue for the twelve months
ending December 31, 2017 grew 25% to $236.7 million, compared to
$189.5 million in 2016;
- 2017 income before income tax provision
was $72.9 million, compared to $53.4 million in 2016;
- 2017 net income was $51.9 million, or
$3.44 per basic and $3.27 per diluted share, compared to a net
income of $81.5 million, or $5.24 per basic and $4.96 per diluted
share in 2016;
- 2017 income tax expense was $21
million, compared to an income tax benefit of $28 million in
2016;
- 2017 Adjusted Non-GAAP net income was
$69.0 million, or $4.57 per basic and $4.34 per diluted share,
compared to Adjusted Non-GAAP net income of $45.9 million, or $2.96
per basic and $2.79 per diluted share in 2016. For a full
reconciliation of Adjusted Non-GAAP net income to the most
comparable GAAP financial measures, please see the tables at the
end of this press release;
- 2017 EBITDA was $96.2 million, compared
to $63.9 million in 2016;
- At year end, Eagle had completed its
$75 million Share Repurchase Program authorized in August 2016 and
purchased an additional $5.8 million in Eagle common stock as part
of its expanded $100 million share buyback program;
- Cash and cash equivalents were $114.7
million, accounts receivable were $53.8 million, and debt was $48.8
million as of December 31, 2017; and,
- 2018 Expense Guidance:
- R&D expense is expected to be in
the range of $46 - $50 million ($39 - $43 million on a non-GAAP
basis)
- SG&A expense is expected to be in
the range of $61 - $64 million ($45 - $48 million on a non-GAAP
basis).
“Eagle had another record year in 2017, with revenue of $237
million and EBITDA of $96 million. We are excited about our
positive meeting with the FDA that will enable us to advance
RYANODEX for EHS, and are planning to conduct another clinical
study at the Hajj in August of this year. And, our fulvestrant
study randomization has now been completed ahead of schedule with
600 subjects. Pending positive data, we remain on track to file an
NDA during the fourth quarter of 2018,” stated Scott Tarriff, Chief
Executive Officer of Eagle Pharmaceuticals.
“Importantly, we filed an ANDA for our first of two assets
earlier this year and intend to file another during the second half
of 2018. Combined branded sales for these assets are approximately
$500 million, representing another significant opportunity to
create value for patients and shareholders,” added Tarriff.
“We remain focused on developing best-in-class injectables and
driving value for shareholders. Given the strength of our pipeline
and multiple upcoming catalysts in 2018, we believe we are
well-positioned to continue to deliver strong results this year,”
concluded Tarriff.
Fourth Quarter 2017 Financial Results
Total revenue for the three months ended December 31, 2017 was
$46.8 million, as compared to $81.1 million for the three months
ended December 31, 2016. A summary of total revenue is outlined
below:
Three Months Ended December
31, 2017 2016 Revenue: Product
sales $ 10,432 $ 9,080 Royalty income 36,353 32,015 License and
other income --- 40,046 Total revenue 46,785 81,141
Product sales were $10.4 million, driven by increases in Bendeka
and Ryanodex, partially offset by a decrease in Argatroban. Royalty
income increased to $36.4 million, as a result of the increased
market share on Teva sales of Bendeka, as well as an increase in
the royalty rate from 20% to 25%.
Research and development expenses decreased $6.8 million to $9.4
million for the three months ended December 31, 2017, compared to
$16.2 million in the prior year quarter. The decrease was largely
due to lower levels of API purchases.
SG&A expenses decreased $4.2 million to $13.4 million in the
fourth quarter of 2017 compared to $17.5 million in the three
months ended December 31, 2016. The decrease was due to the
expiration of the Spectrum promotion contract at the end of June
2017, as well as a reduction in marketing expenses. These
reductions were partially offset by the increase in
personnel-related expenses associated with the expansion of our
sales force in the second quarter of 2017.
During the fourth quarter of 2017, Eagle recorded a tax expense
of $854,000, compared to a tax benefit of $29 million during the
fourth quarter of 2016. The tax provision in the fourth quarter of
2017 was decreased by the recognition of federal R&D tax
credits, offset in part by an adjustment to Eagle’s net deferred
tax asset to reflect the impact of the recently enacted federal tax
reform legislation. The tax provision in the fourth quarter of 2016
was impacted by Eagle’s reversal of the valuation allowance against
the Company’s net deferred tax asset.
Net income for the fourth quarter was $9.1 million, or $0.61 per
basic share and $0.58 per diluted share, compared to net income of
$57.3 million, or $3.75 per basic and $3.52 per diluted share in
the three months ended December 31, 2016, due to the factors
discussed above.
Adjusted Non-GAAP net income for the fourth quarter of 2017 was
$15.6 million, or $1.05 per basic and $1.00 per diluted share,
compared to Adjusted Non-GAAP net income of $17.2 million or $1.12
per basic and $1.05 per diluted share in the prior year quarter.
For a full reconciliation of Adjusted Non-GAAP net income to the
most comparable GAAP financial measures, please see the tables at
the end of this press release.
Full Year 2017 Financial Results
Total revenue for the year ended December 31, 2017 was $236.7
million, as compared to $189.5 million for the year ended December
31, 2016. A summary of total revenue is outlined below:
Year Ended December 31,
2017 2016 Revenue: Product sales $
45,327 $ 40,646 Royalty income 153,880 99,040 License and other
income 37,500 49,796 Total revenue 236,707 189,482
The increase in product sales in 2017 was driven primarily by
the growth in Ryanodex sales. Royalty income increased by $54.8
million to $153.9 million in 2017 from $99.0 million in 2016, due
to increased sales of Bendeka and an increase in the royalty rate
from 20% to 25%. License and other income reflects payments
received for achieving certain contractual milestones in connection
with the Company’s Bendeka licensing agreement with Teva, as well
as an upfront payment associated with the SymBio collaboration
covering Japanese rights for bendamustine hydrochloride
ready-to-dilute and rapid infusion injection products.
Gross margin expanded to 76% in 2017, as compared to 71% in
2016.
R&D expense increased to $32.6 million in 2017, compared to
$28.3 million in 2016 as a result of development efforts to advance
multiple product candidates. Excluding stock-based compensation and
other non-cash and non-recurring items, 2017 R&D expense was
$27.6 million.
SG&A expenses increased by $18.1 million to $71.4 million in
2017, compared to $53.3 million in 2016. The increase in SG&A
expenses related primarily to: (i) increases in personnel-related
expenses due to the expansion of our sales force in the second
quarter of 2017; (ii) marketing expenses associated with pre-launch
EHS disease state awareness initiatives; (iii) increased external
legal expenses; and (iv) staff additions incurred to support
expansion of the Company. These increases were partially offset by
the expiration of the Spectrum promotion contract at the end of
June 2017. Excluding stock-based compensation and other non-cash
and non-recurring items, 2017 SG&A expense was $56.9
million.
For the full year, the Company recorded a tax expense of $21
million, compared to a benefit of $28 million in 2016. The tax
provision in 2017 was decreased by the recognition of federal
R&D tax credits and the impact of employee stock option
exercises. These decreases were partially offset by an adjustment
to Eagle’s net deferred tax asset to reflect the impact of the
recently enacted federal tax reform legislation. The tax provision
in 2016 was impacted by a reversal of a valuation allowance which
had been carried against the Company’s net deferred tax assets. We
anticipate that changes to the corporate tax code will positively
impact Eagle’s tax expense beginning in 2018.
Net income for the year ended December 31, 2017 was $51.9
million or $3.44 per basic and $3.27 per diluted share as compared
to net income of $81.5 million or $5.24 per basic and $4.96 per
diluted share for the year ended December 31, 2016, as a result of
the factors discussed above.
Adjusted Non-GAAP net income for 2017 was $69.0 million, or
$4.57 per basic and $4.34 per diluted share, compared to Adjusted
Non-GAAP net income of $45.9 million, or $2.96 per basic and $2.79
per diluted share in 2016.
Liquidity
As of December 31, 2017, the Company had $114.7 million in cash
and cash equivalents and $53.8 million in net accounts receivable,
$40.0 million of which was due from Teva. In 2017, net cash
provided by operating activities, excluding the increase in net
accounts receivable, was $70.5 million. The Company had $48.8
million in outstanding debt.
As part of our stock repurchase plan, in 2017, we completed our
$75 million Share Repurchase Program authorized in August 2016, and
purchased an additional $5.8 million in Eagle common stock as part
of our expanded $100 million share buyback program.
2018 Expense Guidance
2018 R&D expense is expected to be in the range of $46 - $50
million. This reflects ongoing expenses for the enrollment of
fulvestrant and Ryanodex EHS clinical trials, as well as CMC
outlays in expectation of the 2019 launch of fulvestrant, if
approved. Excluding stock-based compensation and other non-cash and
non-recurring items, R&D expense would be in the range of $39 -
$43 million.
2018 SG&A expense is expected to be in the range of $61 -
$64 million. Excluding stock-based compensation and other non-cash
and non-recurring items, SG&A expense would be in the range of
$45 - $48 million.
Conference Call
As previously announced, Eagle management will host its fourth
quarter and full year 2017 conference call as follows:
Date Monday, February 26, 2018 Time 8:30 A.M.
EST Toll free (U.S.) 866-518-6930 International
203-518-9797
Webcast (live and replay)
www.eagleus.com, under the “Investor
Relations” section
A replay of the conference call will be available for one week
after the call's completion by dialing 800-677-7320 (US) or
402-220-0666 (International) and entering conference call ID
EGRXQ417. The webcast will be archived for 30 days at the
aforementioned URL.
About Eagle Pharmaceuticals, Inc.
Eagle is a specialty pharmaceutical company focused on
developing and commercializing injectable products that address the
shortcomings, as identified by physicians, pharmacists and other
stakeholders, of existing commercially successful injectable
products. Eagle’s strategy is to utilize the FDA's 505(b)(2)
regulatory pathway. Additional information is available on the
Company’s website at www.eagleus.com.
Forward-Looking Statements
This press release contains forward-looking information within
the meaning of the Private Securities Litigation Reform Act of
1995, as amended, and other securities laws. Forward-looking
statements are statements that are not historical facts. Words and
phrases such as “anticipated,” “forward,” “will,” “would,” “may,”
“remain,” “potential,” “prepare,” “expected,” “believe,” “plan,”
“near future,” “belief,” and similar expressions are intended to
identify forward-looking statements. These statements include, but
are not limited to, statements regarding future events including,
but not limited to: the Company’s plans for gaining approval of the
label expansion of RYANODEX to treat EHS patients and other
indications, including the ongoing discussions with the FDA
relating thereto, the planned clinical study of RYANODEX for the
treatment of EHS at the Hajj, and the outcome of such discussions;
the Company’s plans for the development of fulvestrant; the
Company's ability to deliver value in 2018 and over the long term;
and the Company’s timing and ability to repurchase additional
shares of the Company's common stock, if any, under its share
repurchase program. All of such statements are subject to certain
risks and uncertainties, many of which are difficult to predict and
generally beyond Eagle’s control, that could cause actual results
to differ materially from those expressed in, or implied or
projected by, the forward-looking information and statements. Such
risks include, but are not limited to: whether the Company will
incur unforeseen expenses or liabilities or other market factors;
whether the FDA will ultimately approve RYANODEX for the treatment
of EHS and/or other indications; whether the Company can continue
to make progress with the development of fulvestrant; whether the
FDA will ultimately approve Eagle’s ANDA submission; fluctuations
in the trading volume and market price of shares of the Company's
common stock, general business and market conditions and
management's determination of alternative needs and uses of the
Company's cash resources, all of which may affect the Company's
long-term performance and the share repurchase program; the success
of our commercial relationship with Teva and AMRI and the parties’
ability to work effectively together; whether Eagle and Teva will
successfully perform their respective obligations under the license
agreement; difficulties or delays in manufacturing; the
availability and pricing of third party sourced products and
materials; the outcome of litigation involving any of our products
or that may have an impact on any of our products; successful
compliance with the FDA and other governmental regulations
applicable to product approvals, manufacturing facilities, products
and/or businesses; general economic conditions; the strength and
enforceability of our intellectual property rights or the rights of
third parties; competition from other pharmaceutical and
biotechnology companies and the potential for competition from
generic entrants into the market; the timing of product launches;
the successful marketing of our products; the risks inherent in the
early stages of drug development and in conducting clinical trials;
and other factors that are discussed in Eagle’s Annual Report on
Form 10-K for the year ended December 31, 2017, to be filed with
the U.S. Securities and Exchange Commission (SEC) on February 26,
2018 and its other filings with the SEC. Readers are cautioned not
to place undue reliance on these forward-looking statements that
speak only as of the date hereof, and we do not undertake any
obligation to revise and disseminate forward-looking statements to
reflect events or circumstances after the date hereof, or to
reflect the occurrence of or non-occurrence of any events.
Non-GAAP Financial Performance Measures
In addition to financial information prepared in accordance with
U.S. GAAP, this press release also contains adjusted net income and
adjusted earnings per share from continuing operations attributable
to Eagle Pharmaceuticals. The Company believes these measures
provide investors and management with supplemental information
relating to operating performance and trends that facilitate
comparisons between periods and with respect to projected
information.
Adjusted net income from continuing operations excludes
share-based compensation expense, depreciation, amortization of
acquired intangible assets, changes in contingent purchase price,
non-cash interest expense and tax adjustments. The Company believes
these non-GAAP financial measures help indicate underlying trends
in the Company’s business and are important in comparing current
results with prior period results and understanding projected
operating performance. Non-GAAP financial measures provide the
Company and its investors with an indication of the Company’s
baseline performance before items that are considered by the
Company not to be reflective of the Company’s ongoing results. See
the attached Reconciliation of GAAP to Adjusted Non-GAAP Net Income
and Adjusted Non-GAAP Earnings per Share and Reconciliation of GAAP
to Adjusted Non-GAAP EBITDA for explanations of the amounts
excluded and included to arrive at adjusted net income and adjusted
earnings per share amounts, and Adjusted non-GAAP EBITDA amounts,
respectively, for the three and twelve month periods ended December
31, 2017 and 2016.
These adjusted measures are non-GAAP and should be considered in
addition to, but not as a substitute for, the information prepared
in accordance with U.S. GAAP. The Company strongly encourages
investors to review its consolidated financial statements and
publicly-filed reports in their entirety and cautions investors
that the non-GAAP measures used by the Company may differ from
similar measures used by other companies, even when similar terms
are used to identify such measures.
-- Financial tables follow –
EAGLE PHARMACEUTICALS,
INC. CONSOLIDATED BALANCE SHEETS (In thousands,
except per share amounts) December 31,
2017 December 31, 2016 ASSETS Current
assets: Cash and cash equivalents $ 114,657 $ 52,820 Accounts
receivable, net 53,821 42,194 Inventories 5,118 2,739 Prepaid
expenses and other current assets 15,101
11,357 Total current assets 188,697 109,110 Property and
equipment, net 6,820 3,316 Intangible assets, net 23,322 33,372
Goodwill 39,743 39,743 Deferred tax asset, net 11,354 28,643 Other
assets 124 136 Total assets $ 270,060
$ 214,320
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities: Accounts payable $ 11,981 $ 14,716
Accrued expenses 15,391 25,237 Current portion of contingent
consideration 15,055 1,012 Current portion of long-term debt
4,875 — Total current liabilities 47,302
40,965 Contingent consideration, less current portion 709 22,129
Long-term debt, less current portion 42,905 Commitments and
contingencies
Stockholders' equity:
Preferred stock, 1,500,000 shares
authorized and no shares issued oroutstanding as of December 31,
2017 and 2016
— —
Common stock, $0.001 par value; 50,000,000
shares authorized; 16,089,439and 15,890,862 issued as of December
31, 2017 and 2016, respectively
16 16 Additional paid in capital 233,639 213,872 Retained earnings
(Accumulated deficit) 26,284 (25,659 )
Treasury stock, at cost, 1,241,695 and
566,838 shares as of December 31,2017 and 2016, respectively
(80,795 ) (37,003 ) Total stockholders' equity
179,144 151,226 Total liabilities and
stockholders' equity $ 270,060 $ 214,320
EAGLE PHARMACEUTICALS, INC. CONSOLIDATED STATEMENTS OF
INCOME (In thousands, except share and per share
amounts) Three Months Ended
December 31, Year Ended December 31, 2017
2016 2017 2016 (unaudited)
(unaudited) Revenue: Product sales $ 10,432 $ 9,080 $
45,327 $ 40,646 Royalty revenue 36,353 32,015 153,880 99,040
License and other income — 40,046
37,500 49,796 Total revenue 46,785
81,141 236,707 189,482
Operating expenses: Cost of product
sales 9,224 9,836 33,714 35,785 Cost of royalty revenue 4,483 8,983
23,472 19,521 Research and development 9,409 16,164 32,607 28,289
Selling, general and administrative 13,351 17,542 71,416 53,329
Gain on sale of asset — — — (1,750 ) Asset impairment charges — —
7,235 — Changes in fair value of contingent consideration (1,773 )
330 (7,377 ) 957 Legal settlement 1,650 —
1,650 — Total operating expenses
36,344 52,855 162,717
136,131 Income from operations 10,441 28,286 73,990
53,351 Interest income 39 8 91 84 Interest expense (542 )
(2 ) (1,136 ) (8 ) Total other (expense)
income (503 ) 6 (1,045 ) 76
Income before income tax (provision) benefit 9,938
28,292 72,945 53,427 Income tax (provision) benefit (854 )
29,009 (21,002 ) 28,026
Net
income $ 9,084 $ 57,301 $ 51,943 $ 81,453
Earnings per share attributable to common stockholders:
Basic $ 0.61 $ 3.75 $ 3.44 $ 5.24 Diluted $ 0.58 $ 3.52 $ 3.27 $
4.96 Weighted average number of common shares outstanding: Basic
14,890,615 15,293,493 15,102,890 15,533,681 Diluted 15,565,236
16,301,525 15,908,211 16,434,104
EAGLE PHARMACEUTICALS, INC. CONSOLIDATED
STATEMENTS OF CASH FLOWS (In thousands, except share and per
share amounts) Year Ended December 31,
2017 2016 Cash flows from operating
activities: Net income $ 51,943 $ 81,453
Adjustments to reconcile net income to net
cash provided by (usedin) operating activities:
Deferred income taxes 17,289 (30,116 ) Depreciation expense 932 641
Amortization expense 2,815 948 Stock-based compensation 15,429
9,768 Change in fair value of contingent consideration (7,377 ) 957
Amortization of debt issuance costs 222 — Gain on sale of
diclofenac-misoprostol — (1,750 ) Asset impairment charge 7,235 —
Changes in operating assets and liabilities: Increase in
accounts receivable (11,627 ) (15,919 ) (Increase) decrease in
inventory (2,379 ) 12,303 Decrease (increase) in prepaid expenses
and other assets 1,993 (9,430 ) (Decrease) increase in accounts
payable (8,460 ) 10,668 Decrease in deferred revenue — (6,000 )
Decrease (increase) in accrued expenses and other liabilities
(9,096 ) (316 ) Net cash provided by operating
activities 58,919 53,207
Cash flows
from investing activities: Purchase of property and equipment
(4,436 ) (1,590 ) Purchase of short term investments — (62,000 )
Maturities of short term investments — 62,000 Payment for Docetaxel
acquisition — (4,850 ) Payment for Ryanodex intangible asset (750 )
(14,250 ) Purchase of Eagle Biologics, net of cash acquired —
(26,860 ) Proceeds from sale of diclofenac-misoprostol —
1,750 Net cash used in investing activities
(5,186 ) (45,800 )
Cash flows from financing
activities: Repurchases of common stock (43,792 ) (37,003 )
Payment of contingent consideration — (286 ) Proceeds from debt
issuance 50,000 — Payment of debt principal (1,250 ) — Payment of
debt financing costs (1,192 ) — Proceeds from common stock option
exercise 4,338 3,619 Net cash provided
by (used in) financing activities 8,104
(33,670 )
Net increase (decrease) in cash 61,837 (26,263 )
Cash and cash equivalents at beginning of period
52,820 79,083
Cash and cash equivalents at
end of period $ 114,657 $ 52,820
Supplemental disclosures of cash flow information: Cash
paid during the period for: Income taxes $ 10,542 $ 2,800
Interest $ 651 $ 8
Non-cash investing activities Value of
common stock issued for the Eagle Biologics acquisition $ - $ 3,046
Non-cash financing activities Contingent consideration -
business acquisition $ - $ 22,470
EAGLE PHARMACEUTICALS,
INC. RECONCILIATION OF GAAP TO ADJUSTED NON-GAAP NET INCOME
AND ADJUSTED NON-GAAP EARNINGS PER SHARE (In
thousands, except share and per share amounts)
(unaudited) Three Months Ended
December 31, Twelve Months Ended December 31,
2017 2016 2017 2016 Net income
from operations - GAAP $ 9,084 $ 57,301 $ 51,943 $ 81,453
Before tax adjustments: Cost of product revenues: Amortization of
acquired intangible assets (1) 276 284 1,194 746 Gain on sale of
asset (2) (1,750 ) Research and development: Share-based
compensation expense 986 876 3,942 2,914 Depreciation 74 74 Expense
of acquired in-process research & development 1,000 1,000
Selling, general and administrative: Share-based compensation
expense 2,824 1,353 11,487 6,853 Amortization of acquired
intangible assets (3) 405 203 1,620 203 Depreciation 201 180 858
640 Debt issuance costs - 286 - Severance 268 268 Other: Non-cash
interest expense 94 1 238 8 Changes in fair value of contingent
consideration (4) (1,774 ) 330 (7,378 ) 957 Asset impairment charge
- 7,235 - Legal Settlement 1,650 1,650 Tax adjustments (5)
536 (43,370 ) (5,368 ) (46,103 )
Adjusted
Non-GAAP net income $ 15,624 $ 17,158 $ 69,049
$ 45,921 Adjusted Non-GAAP earnings per share
Basic $ 1.05 $ 1.12 $ 4.57 $ 2.96 Diluted $ 1.00 $ 1.05 $ 4.34 $
2.79 Weighted number of common shares outstanding: Basic 14,890,615
15,293,493 15,102,890 15,533,681 Diluted 15,565,236 16,301,525
15,908,211 16,434,104 Explanation of Adjustments: (1)
Amortization of intangible assets for Ryanodex and
Docetaxel. (2) Gain on divestiture of diclofenac-misoprostol. (3)
Amortization of intangible assets for Eagle Biologics. (4) Changes
in the fair value of contingent consideration (Docetaxel and Eagle
Biologics). (5)
Reflects the estimated tax effect of the
pretax adjustments, $3.4 million of tax expense from U.S. tax
reform which is reflected in fourth quarter of 2017 and the
reversal of a tax valuation allowance in the fourth quarter of
2016
EAGLE PHARMACEUTICALS RECONCILIATION OF GAAP TO
ADJUSTED NON-GAAP EBITDA (In thousands)
(unaudited) Three Months Ended
December 31, Twelve Months Ended December 31,
2017 2016 2017 2016 Net income
from operations - GAAP $ 9,084 $ 57,301 $ 51,943 $ 81,453
Add back: Interest expense (income), net 502 (6 ) 1,045 (76 )
Provision for income taxes 854 (29,009 ) 21,002 (28,026 )
Depreciation and amortization 956 667 3,746 1,589 Add back:
- Stock-based compensation 3,811 2,229 15,429 9,768 Changes in fair
value of contingent consideration (1,774 ) 330 (7,378 ) 957 Debt
issuance costs 286 - Asset impairment charges 7,235 - Gain on sale
of asset - (1,750 ) Expense of acquired in-process research &
development 1,000 1,000 Severance 268 268 Legal Settlement 1,650
1,650
Adjusted Non-GAAP EBITDA
$ 16,351 $ 31,512 $ 96,226 $ 63,915
View source
version on businesswire.com: http://www.businesswire.com/news/home/20180226005664/en/
Investor Relations for Eagle Pharmaceuticals,
Inc.:In-Site Communications, Inc.Lisa M. Wilson,
212-452-2793lwilson@insitecony.com
Eagle Pharmaceuticals (NASDAQ:EGRX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Eagle Pharmaceuticals (NASDAQ:EGRX)
Historical Stock Chart
From Sep 2023 to Sep 2024